Zelira Therapeutics has told the ASX it achieved record sales revenue in Q3 FY21 of A$225,000 following strong growth in SprinjeneCBD oral care sales and licensing payments.
The company said the result was its strongest quarterly revenue performance since inception with growth driven largely by the successful December 2020 launch of SprinjeneCBD in the US.
Sales were up 249% on the previous six months.
Zelira Therapeutics managing director Dr Oludare Odumosu said: “Our long-term focus to develop a portfolio of clinically validated and scientifically formulated cannabinoid medicine and consumer products is starting to bear fruit.
“The strong growth in March quarter revenue marks a key turning point for the company. We are well placed to build on the momentum and accelerate our progress in 2021 as we launch new products and expand into new geographies.”